Existential questions about the future of vaccine development have been raised by the refusal of the US Food and Drug Administration (FDA) to approve Moderna’s new flu shot.
On February 3, the Cambridge, Mass.-based pharmaceutical giant received a so-called “refusal-to-file” letter (RTF) from the FDA’s Center for Biologics Evaluation and
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day